Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ESTROSTEP FE vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone acetate produces progestational effects including endometrial transformation and cervical mucus thickening, inhibiting sperm penetration and implantation.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no known contraindications, who have achieved menarche)
Prevention of pregnancy (FDA-approved)
One tablet daily orally, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (24 active tablets) followed by ferrous fumarate 75 mg tablets (4 placebo tablets).
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours. Clinical context: Steady-state reached within 7-10 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Norethindrone acetate: hydrolyzed to norethindrone, then metabolized by reduction and glucuronidation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: ~40% as metabolites; fecal: ~30% (biliary); remainder as conjugates.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Ethinyl estradiol: 97-98% bound to albumin and SHBG; norethindrone acetate: 91-95% bound to albumin and SHBG.
~99% bound to serum albumin and sex hormone-binding globulin.
Ethinyl estradiol: 2.3-3.6 L/kg; norethindrone acetate: 1.5-2.5 L/kg. Indicates extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Ethinyl estradiol ~45% (first-pass metabolism); norethindrone acetate ~64%.
Oral: ~70% due to first-pass metabolism.
No dose adjustment is recommended for patients with mild to moderate renal impairment. Use is contraindicated in patients with severely impaired renal function (GFR <30 m L/min/1.73 m²) due to potential for fluid retention and hyperkalemia.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in patients with acute or chronic hepatic dysfunction (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), use with caution and monitor liver function; no specific dose adjustment guidelines are established.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Safety and efficacy have not been established in pediatric patients below 16 years of age. Post-pubertal adolescents may be dosed as adults, with careful consideration of risks (e.g., bone density).
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in women over 65 years due to lack of efficacy and safety data, and increased risk of cardiovascular and thrombotic events.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and smoking intensity (especially >35 years). Women >35 years who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thromboembolic disorders, cardiovascular disease (MI, stroke), hypertension, gallbladder disease, hepatic neoplasia, lipid effects, glucose intolerance, headache, breakthrough bleeding, depression, contact lens intolerance, fluid retention, hereditary angioedema.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected breast carcinoma, endometrial carcinoma or other estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, cholestatic jaundice of pregnancy or jaundice with prior pill use, hepatic adenoma or carcinoma, pregnancy, hypersensitivity to any component.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food interactions are reported for Estrostep Fe. Grapefruit juice may slightly increase estrogen levels but is not considered clinically significant. There are no dietary restrictions. However, patients should maintain a consistent intake of folic acid if planning pregnancy; iron supplements can be taken with food to reduce GI upset.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Category X. Estrostep FE (norethindrone acetate/ethinyl estradiol/ferrous fumarate) is contraindicated in pregnancy. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects from sex hormones. Second/third trimester: feminization of male fetus, potential for urogenital malformations, and long-term reproductive tract effects. Postnatal: possible increased risk of childhood cancers.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in breast milk in small amounts (estrogen M/P ratio ~0.2, progestin M/P ratio ~0.6). May reduce milk quantity and quality. Use caution; generally not recommended. No adverse effects reported in infants at typical doses.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated; no dose adjustment needed because drug should be discontinued immediately if pregnancy occurs. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) not applicable due to contraindication.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Estrostep Fe is a combined oral contraceptive containing norethindrone acetate and ethinyl estradiol. It is unique among OCPs for its step-up estrogen regimen (20, 30, 35 mcg EE) intended to mimic natural menstrual cycle. Clinicians should note that it is not FDA-approved for acne treatment, though it is often used off-label; only Estrostep (non-Fe) is approved for acne. The iron (ferrous fumarate) in the last 7 tablets is a placebo. It is a low-dose pill; missed doses more likely cause breakthrough bleeding. Contraindications include smoking >35, history of DVT/PE, migraine with aura, liver disease, breast cancer. Counsel patients to take at same time daily; if missed, follow standard missed pill protocol.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill at the same time each day. The first 21 pills contain active hormones; the last 7 pills are iron tablets (not hormones).,If you miss a pill, refer to the package insert or contact your healthcare provider. Use backup contraception (condoms) if pills are missed.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding, especially in the first few months.,Estrostep Fe does not protect against sexually transmitted infections (STIs). Always use condoms for STI prevention.,Smoking while using this pill increases risk of serious cardiovascular events. Do not smoke.,Contact your doctor if you experience signs of a blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.,The iron in the last 7 pills is to help with iron levels but does not provide hormonal contraception during that week.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ESTROSTEP FE vs AFIRMELLE, answered by our medical review team.
ESTROSTEP FE is a Combined Oral Contraceptive that works by Combination estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone acetate produces progestational effects including endometrial transformation and cervical mucus thickening, inhibiting sperm penetration and implantation.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ESTROSTEP FE and AFIRMELLE depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ESTROSTEP FE is: One tablet daily orally, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (24 active tablets) followed by ferrous fumarate 75 mg tablets (4 placebo tablets).. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ESTROSTEP FE and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ESTROSTEP FE is classified as Category C. Category X. Estrostep FE (norethindrone acetate/ethinyl estradiol/ferrous fumarate) is contraindicated in pregnancy. First trimester: increased risk of neural tube defects, cardiov. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.